Treatment of Raoultella ornithinolytica Infection
For Raoultella ornithinolytica infections, treat with carbapenems (meropenem or imipenem) as first-line therapy, or third-generation cephalosporins (ceftriaxone or cefotaxime) as alternatives, with fluoroquinolones (ciprofloxacin or levofloxacin) reserved for less severe cases or based on susceptibility testing.
Antibiotic Selection Algorithm
Severe Infections (Bacteremia, Abdominal Abscess, Emphysematous Pyelonephritis)
- First choice: Meropenem or imipenem 1, 2, 3
- Alternative: Third-generation cephalosporins (ceftriaxone, cefotaxime) 4
- Duration: Continue until clinical resolution and source control achieved
Moderate Infections (Urinary Tract, Respiratory)
- First choice: Third-generation cephalosporins 4
- Alternative: Fluoroquinolones (ciprofloxacin, levofloxacin) 1, 5
- For external otitis specifically: Oral ciprofloxacin with topical levofloxacin 5
Metallo-Beta-Lactamase (MBL)-Producing Strains
- Aminoglycosides (amikacin) with therapeutic drug monitoring 6
- Carbapenems are ineffective against MBL-producers
- Antimicrobial stewardship team consultation recommended 6
Critical Clinical Considerations
High-Risk Populations Requiring Aggressive Treatment
- Immunocompromised patients (malignancy, chemotherapy) 4
- Neonates and infants with congenital malformations 4
- Elderly patients with diabetes mellitus 3, 7
- Patients with invasive procedures (ventilation, urinary catheters, CRRT) 4
Source Control is Mandatory
- Percutaneous drainage for abscesses 1, 3
- Surgical debridement when indicated 1
- Remove foreign bodies and invasive devices 8
- Drainage is as critical as antibiotic selection for treatment success 3
Resistance Patterns and Pitfalls
Critical warning: R. ornithinolytica demonstrates increasing multidrug resistance with carbapenemase production becoming more common 9. All characterized isolates in recent surveillance carried 5-20 antibiotic resistance genes 9. This makes empiric therapy challenging and underscores the absolute necessity of:
- Obtaining cultures before starting antibiotics (blood, urine, drainage fluid, or tissue as appropriate)
- Performing susceptibility testing on all isolates 5, 4
- Adjusting therapy based on susceptibility results rather than continuing empiric coverage
Documented Susceptibility Profile
Based on pediatric and adult case series, R. ornithinolytica typically shows susceptibility to:
- Carbapenems (when not MBL-producing)
- Third-generation cephalosporins
- Fluoroquinolones
- Aminoglycosides 4
Special Clinical Presentations
Neonatal/Pediatric Infections
Look for: dyspnea, hypoxemia, skin flushing, systemic erythema, and leukocytosis 4. These are positive diagnostic clues. Blood culture is the primary diagnostic method 4. Prognosis is poor in septic presentations 4.
Neurologic Presentations
Advanced age may be a significant risk factor even in immunocompetent hosts 7. Encephalopathy can be the presenting feature with genitourinary source 7.
Post-Surgical Infections
Invasive procedures dramatically increase infection risk 1, 2. Gastric fistulas and biliary tract procedures are particular risk factors 1.
Treatment Duration and Monitoring
- Continue antibiotics until clinical resolution (defervescence, normalization of inflammatory markers)
- Monitor for treatment failure requiring drainage or surgical intervention
- For aminoglycoside use: mandatory therapeutic drug monitoring to prevent nephrotoxicity and ototoxicity 6
- Blood glucose control is essential in diabetic patients with emphysematous complications 3